Clinical features and management of three patients under bDMARD or tsDMARD during COVID-19 admission
| Characteristics | Patient 1 | Patient 2 | Patient 3 |
| Sex (M/F) | F | F | M |
| Age (years) | 75 | 54 | 66 |
| Rheumatic disease | Rheumatoid arthritis RF+ | Rheumatoid arthritis (RF−, ACPA−) | Psoriatic arthritis |
| Years since diagnosis | 18 | 2 | 9 |
| Current bDMARD/tsDMARD | Baricitinib 4 mg/day | Etanercept 50 mg/week | Adalimumab 40 mg/2 weeks |
| Current DMARD | Methotrexate 10 mg/week Hydroxychloroquine 400 mg | ||
| Previous treatment | Etanercept Baricitinib Methotrexate Leflunomide | Etanercept Methotrexate Leflunomide Hydroxychloroquine | Adalimumab Methotrexate |
| Disease activity (date) | DAS28 4,26 (9 March 2020) | DAS28: 4,08. (27 January 2020) | DAS28: 1,61. DAPSA: 0,2. (12 December 2019) |
| Hypertension and treatment | Yes Valsartan Hydrochlorothiazide | No | Yes No treatment |
| Diabetes mellitus and treatment | No | No | No |
| Dyslipidaemia and treatment | Yes Atorvastatin | No | Yes Pravastatin Gemfibrozil |
| BMI (kg/m2) | 21.9 | 28.4 | 35.38 |
| Other comorbidities | Asthma | No | No |
| Smoking | No | Former smoker | No |
| Alcohol | No | No | Yes |
| Recreational drugs | No | No | No |
| Days from symptoms onset to hospital admission | 22 | 15 | 10 |
| Clinical symptoms | Cough | Cough, fever, fatigue | Cough, dyspnoea |
| Radiological pattern | Normal | Peripheral bilateral interstitial infiltrate | Peripheral bilateral interstitial infiltrate |
| PCR for SARS-CoV-2 | + | + | + |
| Ferritin at admission and maximum | 42 61 | 404 690 | 1044 1179 |
| IL-6 at admission | 11 | 36 | 22 |
| LDH on admission and maximum | 219 253 | 252 327 | 201 264 |
| D-Dimer at admission | 0.59 | 3,72 | 0.75 |
| Lymphocytes | 570 | 660 | 850 |
| Treatment for COVID-19 | Hydroxychloroquine | Hydroxychloroquine Azithromycin | Hydroxychloroquine Azithromycin Methylprednisolone Colchicine |
| Worst PaO2/FiO2 (PaFi) or SatO2/O2 (SpaFi) | SpaFi 452 | SpaFi 443 | SpaFi 448 |
| Oxygen therapy, nasal cannula, non-invasive ventilation, high-flow oxygen support | No | No | No |
| Intensive care unit | No | No | No |
| Orotracheal intubation or invasive mechanical ventilation | No | No | No |
| Complications (deep vein thrombosis, pulmonary embolism, cardiac arrhythmia, bacterial infection, death) | No | Acute pyelonephritis | No |
bDMARD, biological DMARD; BMI, body mass index; DMARD, disease-modifying antirheumatic drug; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; tsDMARD, targeted synthetic DMARD.